184 related articles for article (PubMed ID: 12464588)
1. Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Ann Surg Oncol; 2002 Dec; 9(10):968-74. PubMed ID: 12464588
[TBL] [Abstract][Full Text] [Related]
2. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
3. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
4. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
5. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
6. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
[TBL] [Abstract][Full Text] [Related]
7. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
Vrouenraets BC; Hart GA; Eggermont AM; Klaase JM; van Geel BN; Nieweg OE; Kroon BB
J Am Coll Surg; 1999 May; 188(5):522-30. PubMed ID: 10235581
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
9. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.
Lindnér P; Doubrovsky A; Kam PC; Thompson JF
Ann Surg Oncol; 2002 Mar; 9(2):127-36. PubMed ID: 11888868
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and morbidity of isolated limb perfusion.
Vrouenraets BC; Klaase JM; Nieweg OE; Kroon BB
Semin Surg Oncol; 1998; 14(3):224-31. PubMed ID: 9548605
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
18. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
[TBL] [Abstract][Full Text] [Related]
19. TNF dose reduction in isolated limb perfusion.
Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
[TBL] [Abstract][Full Text] [Related]
20. Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.
Madu MF; Deken MM; van der Hage JA; Jóźwiak K; Wouters MWJM; van Akkooi ACJ
Ann Surg Oncol; 2017 Jul; 24(7):1997-2005. PubMed ID: 28188500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
